Plain-English translation of NCT07051629 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Epilepsy research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage safety study of , a new medication designed to treat epilepsy by targeting the underlying causes of seizures. Researchers will give increasing doses of (or a placebo) intravenously to healthy volunteers first, and then to people who have epilepsy and are not fully controlled on current medications. The goal is to understand how safe the medication is, how well it's tolerated, and how the body processes it.
Current anti-seizure medications don't work well enough for everyone with epilepsy. This new treatment addresses the root causes of seizures in a different way, and researchers need to test whether it's safe for people to use before moving to larger, longer studies.
You likely qualify if…
You likely don't qualify if…
If you're selected, you'll receive an intravenous (IV) infusion of either the medication or a placebo over one hour. Healthy volunteers will get small doses first, and if those are safe, people with epilepsy will receive the medication while their seizure activity is monitored. The study involves starting with low doses and gradually increasing them, with blood tests, heart monitoring (EKG), and regular check-ins to watch for any side effects. Your epilepsy medications will stay the same throughout the study to help researchers understand how the new treatment works on its own.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
United States